In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Bone Marrow Transplantation

• Publication date

  2000-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.bmt.1702431PMID 10918410
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of Interleukin‐2 Induced Interleukin‐5 and Interleukin‐13 Production in Human Peripheral Blood Mononuclear Cells

  2000cited by this paper
• Additive effects of infection and neutropenia on the induction of granulocytopoietic activity in vivo

  1999cited by this paper
• In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients.

  1998cited by this paper
• Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects.

  1998cited by this paper
• Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2.

  1997cited by this paper
• Differential Role for IL‐2 and IL‐15 in the Inhibition of Apoptosis in Short Term Activated Human Lymphocytes

  1997cited by this paper
• High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation

  1997cited by this paper
• The role of interleukin-10 (IL-10) in IL-15-mediated T-cell responses.

  1997cited by this paper
• Peripheral blood mononuclear cells from autologous hematopoietic stem cell transplantation recipients produce and respond to IL-12.

  1996cited by this paper
• Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapy.

  1995cited by this paper
• Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration.

  1995cited by this paper
• Time course of interferon-gamma production deficiency after autologous and allogeneic stem cell transplantation for malignancies.

  1995cited by this paper
• Effects of interleukin-2 on gene expression in human neutrophils.

  1995cited by this paper
• Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution.

  1994cited by this paper
• Induction of two distinct natural killer-cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children with solid tumors.

  1994cited by this paper
• Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma.

  1993cited by this paper
• Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expression.

  1993cited by this paper
• Interleukin‐2: Use in solid tumors

  1993cited by this paper
• IL‐2 infusion abrogates humoral immune responses in humans

  1992cited by this paper
• In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients

  1991cited by this paper
• In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophages colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients.

  1991cited by this paper
• Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer.

  1991cited by this paper
• Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation

  1991cited by this paper
• Adoptive immunotherapy with high-dose interleukin-2: kinetics of circulating progenitors correlate with interleukin-6, granulocyte colony-stimulating factor level.

  1991cited by this paper
• Bone Marrow Transplant

  1990cited by this paper
• Interleukin‐2 Augmentation of Interleukin‐1 and Prostaglandin E2 Production

  1989cited by this paper
• In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation.

  1989cited by this paper
• Induction of circulating tumor necrosis factor (TNFα) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients

  1988cited by this paper

• Immunotherapy for Pediatric Solid Tumors

  2020cites this paper
• Association between functional polymorphisms in IL‐33/ST2 pathway and risk of osteosarcoma

  2018influential citation
• A fluorescent microbead-based microfluidic immunoassay chip for immune cell cytokine secretion quantification.

  2018cites this paper
• Profiling multiple cytokine levels in a mixing-enhanced microfluidic immunoassay

  2017cites this paper
• Specificities of Autologous Haematopoietic Stem Cell Transplantation in Children: A Single Centre Experience

  2014cites this paper
• Cellular immunotherapy strategies for Ewing sarcoma.

  2014cites this paper
• The molecular pathogenesis of Ewing sarcoma

  2010cites this paper
• Robust network calibration and therapy design in systems biology

  2010cites this paper
• Immunologic and Therapeutic Synergy of IL-27 and IL-2: Enhancement of T Cell Sensitization, Tumor-Specific CTL Reactivity and Complete Regression of Disseminated Neuroblastoma Metastases in the Liver and Bone Marrow1

  2009cites this paper
• Bone Marrow Neuroblastoma Metastases in the Liver and and Complete Regression of Disseminated Sensitization , Tumor-Specific CTL Reactivity IL-27 and IL-2 : Enhancement of T Cell Immunologic and Therapeutic Synergy of and

  2009cites this paper
• Changes in cytokine profile during local IL-2 therapy in cancer patients.

  2006cites this paper
• Immunology and Immunotherapy

  2005cites this paper
• Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients.

  2005cites this paper
• Megatherapy and stem cell transplantation for Ewing's family of tumors: A critical review of current literature

  2004influential citation
• IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial

  2003cites this paper
• The Neurology of Neuroblastoma

  2002cites this paper
• CO-OPERATION OF IL-1 AND IL-2 ON T-CELL ACTIVATION IN MONONUCLEAR CELL CULTURES

  2001cites this paper
• Molecular Regulation of Immune Recognition Molecule Expression by Breast Cancer Cells

  1999cites this paper